J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in

Read the full 202 word article

User Sign In